We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
Read MoreHide Full Article
Shares of IRIDEX Corporation (IRIX - Free Report) have declined 15.2% since the company reported its earnings for the quarter ended July 4, 2026. This compares to the S&P 500 index’s 1% decline over the same time frame. Over the past month, the stock has declined 16% against the S&P 500’s 3.5% gain.
IRIDEX incurred a second-quarter 2026 net loss of 7 cents per share, wider than a loss of 6 cents per share a year earlier.
Revenues of $12.6 million denoted a 7% decline from $13.6 million in the year-ago quarter, primarily due to lower retina product sales, partly offset by continued growth in glaucoma probe sales.
Net loss widened to $1.3 million from $1 million a year earlier. Gross profit declined to $4.3 million from $4.7 million, while gross margin was relatively stable at 34.2% versus 34.5%. Operating expenses decreased 5% year over year to $5.3 million. Adjusted EBITDA was a loss of $0.4 million compared with positive adjusted EBITDA of $0.02 million in the prior-year period.
IRIDEX Corporation Price, Consensus and EPS Surprise
Cyclo G6 product family revenues increased 19% year over year to $3.9 million from $3.3 million, supported by strong probe demand. IRIDEX sold 17,700 Cyclo G6 probes, up roughly 35% from 13,100 a year earlier, reflecting increased utilization of the G6 platform. However, Cyclo G6 laser system sales declined to 18 units from 35, with management citing order timing in Europe, the Middle East and Africa and competitive pressure on new console placements. Retina product revenues fell to $6.5 million from $8 million, while other revenues remained essentially flat at $2.2 million.
Balance Sheet Update
IRIDEX ended the quarter with cash and cash equivalents of $4.7 million, down from $6 million as of Jan 3, 2026. As of July 4, inventories stood at $9.8 million, up from $7.9 million at Jan. 3, 2026, while total assets declined to $27.3 million from $29.2 million.
Total stockholders’ equity declined to $3.6 million from $4.9 million over the same period.
Management Highlights Cost and Commercial Initiatives
Management characterized the quarter as an important step in IRIDEX's efforts to reshape its financial profile, pointing to positive cash flow, cost controls and improved working-capital management. The company is targeting greater G6 utilization by focusing on existing accounts with moderate usage and high-volume glaucoma practices that have not yet incorporated MicroPulse therapy. Management also cited Medicare local coverage determination tailwinds and higher U.S. average selling prices as contributors to glaucoma momentum.
For retina, management said underlying demand remained intact despite weaker reported sales. The company expects the second half of 2026 to deliver low-single-digit retina growth, aided by progress on international regulatory approvals, U.S. promotional activity and improved commercial execution. Management also expects low-double-digit glaucoma growth in the second half, although some second-quarter probe demand reflected pre-orders associated with anticipated regulatory blackout periods.
International Factors Pressure Headline Results
The revenue decline was concentrated in retina and reflected international commercial transitions and regulatory-related issues. Middle East disruptions weighed on sales, while China was affected by regulatory constraints and distributors working through existing inventory. Gross-margin benefits from higher-margin glaucoma probes were largely offset by softer retina system margins and other cost pressures. Meanwhile, lower general and administrative expenses stemming from the company's administrative-function transfer initiative helped reduce overall operating expenses.
2026 Outlook Reaffirmed
IRIDEX reaffirmed full-year 2026 revenue guidance of $51-$53 million. Management noted that the outlook excludes Middle East revenues and represents roughly 1-5% pro forma growth from 2025 when prior-year Middle East revenues are excluded. The company also maintained its expectation for adjusted operating expenses, excluding depreciation and amortization and stock-based compensation, of $19-$19.5 million.
Other Developments
IRIDEX continued its restructuring efforts, including relocating its headquarters to a lower-cost facility and shifting production to lower-cost third-party contract manufacturers. To protect international supply during the transition and potential regulatory blackout periods, the company is building additional inventory. Management expects the restructuring initiatives to improve operating efficiency and support gross-margin improvement, although the inventory investment is expected to reduce cash on hand through 2026 before reversing as inventory levels are worked down in 2027.
View the Zacks #1 Rank List
Image: Bigstock
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
Shares of IRIDEX Corporation (IRIX - Free Report) have declined 15.2% since the company reported its earnings for the quarter ended July 4, 2026. This compares to the S&P 500 index’s 1% decline over the same time frame. Over the past month, the stock has declined 16% against the S&P 500’s 3.5% gain.
IRIDEX incurred a second-quarter 2026 net loss of 7 cents per share, wider than a loss of 6 cents per share a year earlier.
Revenues of $12.6 million denoted a 7% decline from $13.6 million in the year-ago quarter, primarily due to lower retina product sales, partly offset by continued growth in glaucoma probe sales.
Net loss widened to $1.3 million from $1 million a year earlier. Gross profit declined to $4.3 million from $4.7 million, while gross margin was relatively stable at 34.2% versus 34.5%. Operating expenses decreased 5% year over year to $5.3 million. Adjusted EBITDA was a loss of $0.4 million compared with positive adjusted EBITDA of $0.02 million in the prior-year period.
IRIDEX Corporation Price, Consensus and EPS Surprise
IRIDEX Corporation price-consensus-eps-surprise-chart | IRIDEX Corporation Quote
Glaucoma Growth Offsets Retina Weakness
Cyclo G6 product family revenues increased 19% year over year to $3.9 million from $3.3 million, supported by strong probe demand. IRIDEX sold 17,700 Cyclo G6 probes, up roughly 35% from 13,100 a year earlier, reflecting increased utilization of the G6 platform. However, Cyclo G6 laser system sales declined to 18 units from 35, with management citing order timing in Europe, the Middle East and Africa and competitive pressure on new console placements. Retina product revenues fell to $6.5 million from $8 million, while other revenues remained essentially flat at $2.2 million.
Balance Sheet Update
IRIDEX ended the quarter with cash and cash equivalents of $4.7 million, down from $6 million as of Jan 3, 2026. As of July 4, inventories stood at $9.8 million, up from $7.9 million at Jan. 3, 2026, while total assets declined to $27.3 million from $29.2 million.
Total stockholders’ equity declined to $3.6 million from $4.9 million over the same period.
Management Highlights Cost and Commercial Initiatives
Management characterized the quarter as an important step in IRIDEX's efforts to reshape its financial profile, pointing to positive cash flow, cost controls and improved working-capital management. The company is targeting greater G6 utilization by focusing on existing accounts with moderate usage and high-volume glaucoma practices that have not yet incorporated MicroPulse therapy. Management also cited Medicare local coverage determination tailwinds and higher U.S. average selling prices as contributors to glaucoma momentum.
For retina, management said underlying demand remained intact despite weaker reported sales. The company expects the second half of 2026 to deliver low-single-digit retina growth, aided by progress on international regulatory approvals, U.S. promotional activity and improved commercial execution. Management also expects low-double-digit glaucoma growth in the second half, although some second-quarter probe demand reflected pre-orders associated with anticipated regulatory blackout periods.
International Factors Pressure Headline Results
The revenue decline was concentrated in retina and reflected international commercial transitions and regulatory-related issues. Middle East disruptions weighed on sales, while China was affected by regulatory constraints and distributors working through existing inventory. Gross-margin benefits from higher-margin glaucoma probes were largely offset by softer retina system margins and other cost pressures. Meanwhile, lower general and administrative expenses stemming from the company's administrative-function transfer initiative helped reduce overall operating expenses.
2026 Outlook Reaffirmed
IRIDEX reaffirmed full-year 2026 revenue guidance of $51-$53 million. Management noted that the outlook excludes Middle East revenues and represents roughly 1-5% pro forma growth from 2025 when prior-year Middle East revenues are excluded. The company also maintained its expectation for adjusted operating expenses, excluding depreciation and amortization and stock-based compensation, of $19-$19.5 million.
Other Developments
IRIDEX continued its restructuring efforts, including relocating its headquarters to a lower-cost facility and shifting production to lower-cost third-party contract manufacturers. To protect international supply during the transition and potential regulatory blackout periods, the company is building additional inventory. Management expects the restructuring initiatives to improve operating efficiency and support gross-margin improvement, although the inventory investment is expected to reduce cash on hand through 2026 before reversing as inventory levels are worked down in 2027.